Phase II pilot study of bortezomib (Velcade) and gemcitabine for patients with relapsed or refractory Hodgkin's lymphoma

Trial Profile

Phase II pilot study of bortezomib (Velcade) and gemcitabine for patients with relapsed or refractory Hodgkin's lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Gemcitabine (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jul 2007 Status changed from recruiting to in progress.
    • 16 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top